NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) announced its earnings results on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to analyst estimates of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business's revenue was up 23.3% compared to the same quarter last year. During the same period last year, the firm posted $0.88 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, October, 31st. The company provided EPS guidance of $4.22-4.27 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.91 billion.PRA Health Sciences also updated its FY 2018 guidance to $4.22-4.27 EPS.

8 equities research analysts have issued twelve-month price targets for PRA Health Sciences' stock. Their predictions range from $100.00 to $120.00. On average, they expect PRA Health Sciences' stock price to reach $113.50 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

News coverage about PRAH stock has been trending positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PRA Health Sciences earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the near term.

PRA Health Sciences saw a increase in short interest in November. As of November 15th, there was short interest totalling 2,167,365 shares, an increase of 40.9% from the October 31st total of 1,538,009 shares. Based on an average trading volume of 548,492 shares, the short-interest ratio is presently 4.0 days. Approximately 3.8% of the shares of the stock are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.44%), Vanguard Group Inc. (8.95%), Vanguard Group Inc (8.95%), Bank of New York Mellon Corp (3.83%), FMR LLC (3.60%) and Eagle Asset Management Inc. (1.67%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Panagora Asset Management Inc., Pictet Asset Management Ltd., Allianz Asset Management GmbH, Paloma Partners Management Co, Tygh Capital Management Inc., Vaughan Nelson Investment Management L.P. and Wells Fargo & Company MN. Company insiders that have sold PRA Health Sciences company stock in the last year include David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, Frontier Capital Management Co. LLC, Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., AQR Capital Management LLC, Laurion Capital Management LP and Bank of New York Mellon Corp. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $99.72.

PRA Health Sciences has a market capitalization of $6.48 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]